Contribution of pulmonary vasoconstriction to haemodynamic instability after acute pulmonary embolism. Implications for treatment?

Netherlands Journal of Medicine

Volumn 58, Issue 6, 2001, Pages 241-247

  Smulders, Yvo M ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cyclooxygenase inhibitors; Pulmonary embolism; Pulmonary vasoconstriction; Serotonin; Thromboxane A2

Indexed keywords

HYDRALAZINE; KETANSERIN; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SEROTONIN; SEROTONIN ANTAGONIST; THROMBOXANE A2; VASODILATOR AGENT;

ACUTE DISEASE; ANIMAL MODEL; BLOOD CLOT LYSIS; CATHETER; EMBOLECTOMY; HEART AFTERLOAD; HEMODYNAMICS; HUMAN; HYPOTHESIS; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; LUNG VASOCONSTRICTION; MORTALITY; NONHUMAN; PRACTICE GUIDELINE; REVIEW;

ANIMALS; EMBOLECTOMY; FIBRINOLYTIC AGENTS; HEMODYNAMIC PROCESSES; HUMANS; PULMONARY EMBOLISM; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 0034958539     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(01)00117-6     Document Type: Review

References (48)

1. Thrombolytic therapy for pulmonary embolism
2. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy
3. Massive pulmonary embolism. Diagnostic and therapeutic strategies
4. The haemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease
5. Determinants of right ventricular function and hemodynamics after pulmonary embolism
6. Pulmonary physiology during pulmonary embolism
7. Cardiorespiratory changes in patients undergoing pulmonary resection using different anesthetic management techniques
8. Pulmonary hypertension secondary to minor pulmonary embolism
9. Natural history of pulmonary embolism
10. Humoral transmission of cardiorespiratory changes in experimental lung embolism
11. Thromboxane mediation of cardiopulmonary effects of embolism
12. 2 and prostacyclin following experimental acute pulmonary embolism
13. The effects of aspirin and methysergide on responses to clot-induced pulmonary embolism
14. The effects of aspirin and methysergide, singly and in combination, on systemic haemodynamic responses to pulmonary embolism
15. Prostaglandin control of plasma and platelet 5-hydroxytryptamine in normal and embolized animals
16. Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension
17. Reduction of platelet serotonin and the response to pulmonary emboli
18. Platelet mediated pulmonary hypertension and hypoxia during pulmonary microembolism. Reduction by platelet inhibition
19. Humoral factors in massive pulmonary embolism: an experimental study
20. Platelet adherence to thromboemboli in relation to the pathogenesis and treatment of pulmonary embolism
21. Role of platelets in sudden death induced by experimental pulmonary emboli
22. Therapeutic benefits of 5-hydroxytryptamine inhibition following pulmonary embolism
23. The role of endothelin-1 as a mediator of the pressure response after air embolism in blood perfused lungs
24. 2 to the acute cardiopulmonary changes of pulmonary embolism
25. Hypoxic pulmonary vasoconstriction and gas exchange in acute canine pulmonary embolism
26. Cyclooxygenase inhibition aggravates pulmonary hypertension and deteriorates gas exchange in canine pulmonary hypertension
27. Thromboxane generation after thrombin. Protective effect of thromboxane synthetase inhibition on lung fluid balance
28. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression
29. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial
30. Effects of aspirin on outcome of acute pulmonary embolism in the Pulmonary Embolism Prevention trial
31. Cardiopulmonary effects of ketanserin infusion in human pulmonary embolism
32. Endothelin-1 and serotonin: mediators of primary and secondary pulmonary hypertension?
33. Pulmonary vascular effects of hydralazine in a canine preparation of pulmonary thromboembolism
34. Oral hydralazine therapy for acute pulmonary embolism and low output state
35. Treatment of pulmonary embolism with prostacyclin
36. Selective pulmonary vasodilatory effect of ZSY-27 in dogs with pulmonary hypertension due to pulmonary embolism
37. Haemodynamic effects of amrinone in a canine model of massive pulmonary embolism
38. The use of inhaled aerosolized prostacyclin in the treatment of pulmonary hypertension secondary to pulmonary embolism
39. Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets
40. Chronic pulmonary hypertension due to recurrent microembolism in pig and its response to inhaled nitric oxide
41. Inhaled nitric oxide partially reverses pulmonary hypertension in a canine model of acute pulmonary embolism
42. Small-dose inhaled nitric oxide attenuates haemodynamic changes after pulmonary air embolism in dogs
43. Inhaled nitric oxide in patients with pulmonary embolism
44. Use of inhaled nitric oxide in pulmonary embolism
45. Inhaled nitric oxide in a patient with severe pulmonary embolism
46. Clinical and haemodynamic correlates in pulmonary embolism
47. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction